Author of the article:
Article content
- PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] launched in the U.S. at the end of Q1 2022 – advancing through commercial stage gates required to enable broad access to the 3-antigen adult hepatitis B (HBV) vaccine
- FDA Orphan Drug Designation received for VBI-1901 for treatment of glioblastoma (GBM) in June 2022
- Two new clinical studies in GBM patients expected to start before the end of 2022
- In partnership with the Government of Canada, new clinical study assessing pan-coronavirus vaccine candidate…
